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AbstrAct
Introduction One of the most debilitating symptoms 
of malignant pleural mesothelioma (MPM) is dyspnoea 
caused by pleural effusion. MPM can be complicated by 
the presence of tumour on the visceral pleura preventing 
the lung from re-expanding, known as trapped lung 
(TL). There is currently no consensus on the best way to 
manage TL. One approach is insertion of an indwelling 
pleural catheter (IPC) under local anaesthesia. Another 
is video-assisted thoracoscopic partial pleurectomy/
decortication (VAT-PD). Performed under general 
anaesthesia, VAT-PD permits surgical removal of the rind of 
tumour from the visceral pleura thereby allowing the lung 
to fully re-expand.
Methods and analysis MesoTRAP is a feasibility study 
that includes a pilot multicentre, randomised controlled 
clinical trial comparing VAT-PD with IPC in patients with 
TL and pleural effusion due to MPM. The primary objective 
is to measure the SD of visual analogue scale scores 
for dyspnoea following randomisation and examine the 
patterns of change over time in each treatment group. 
Secondary objectives include documenting survival and 
adverse events, estimating the incidence and prevalence 
of TL in patients with MPM, examining completion of 
alternative forms of data capture for economic evaluation 
and determining the ability to randomise 38 patients in 18 
months.
Ethics and dissemination This study was approved by 
the East of England-Cambridge Central Research Ethics 
Committee and the Health Research Authority (reference 
number 16/EE/0370). We aim to publish the outputs of this 
work in international peer-reviewed journals compliant 
with an Open Access policy.
trial registration NCT03412357.
IntroductIon
Malignant pleural mesothelioma (MPM) is a 
rare cancer affecting the pleura, closely asso-
ciated with previous exposure to asbestos. 
Although the import and use of asbestos has 
been banned in over 60 countries worldwide, 
including the UK, MPM remains a major clin-
ical and public health problem.1
MPM caused 2542 deaths in the UK in 
2015, and globally, mesothelioma is estimated 
to cause 38 400 deaths per year.2 3 Epidemi-
ological data indicate that 65 000 deaths are 
expected between 2002 and 2050 in the UK 
alone.4 Currently, median survival is around 
9.5 months, there is no known cure and treat-
ment is palliative.5 Only Pemetrexed and 
platinum-based chemotherapy have been 
shown to offer a significant benefit providing 
a modest survival increase of 8–10 weeks.6
One of the most debilitating symptoms for 
patients with MPM is breathlessness caused by 
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the build-up of fluid in the pleural space. As the pleural 
effusion increases, symptoms become more severe, and 
patients are often referred for drainage and a talc pleu-
rodesis, with a view to preventing recurrence.
An effective pleurodesis is dependent on apposition 
of visceral and parietal pleura. In mesothelioma, it is 
common for tumour to be present on the visceral surface 
of the lung. This can prevent the lung from fully rein-
flating following fluid removal, meaning that the visceral 
and parietal pleura cannot appose. This situation is called 
‘trapped lung’ (TL).
When the lung is trapped, the fluid recurs leading to 
repetitive cycles of breathlessness, drainage and fluid 
reaccumulation. This leads to repeated hospital atten-
dances with associated healthcare costs as well as distress 
and inconvenience to the patient and their families. 
Furthermore, the pleural space can become loculated 
such that subsequent aspirations/drains are less effective, 
and the risk of pleural infection is increased with subse-
quent morbidity and mortality.
Rather than repeated pleural aspirations/drains, some 
clinicians are now using an indwelling pleural catheter 
(IPC) to manage TL. Inserted under local anaesthesia as 
a day case procedure, an IPC is a soft silicone catheter 
with a one-way valve at the distal end. Generally well toler-
ated, it can drain fluid for weeks to months. Spontaneous 
pleurodesis is thought to develop in around 20% of cases, 
allowing the IPC to be removed.7 8 However, complica-
tions such as pleural infection (<5%), blockage (20%) 
or displacement can occur requiring removal or replace-
ment, and for some, the presence of the catheter acts as 
a constant reminder of the underlying disease.9 10 Place-
ment of an IPC may also be dependent on availability 
of a community-based healthcare professional to drain 
fluid 2–3 times weekly if the patient cannot manage this 
independently.
An alternative approach often favoured by thoracic 
surgeons is video-assisted thoracoscopic partial pleu-
rectomy/decortication (VAT-PD).11 Performed under 
general anaesthesia, VAT-PD permits surgical removal 
of the rind of tumour from the visceral pleura, thereby 
allowing the lung to fully expand again. Simultaneous 
removal of mesothelioma from the parietal pleura 
allows pleurodesis to occur. The advantage of this 
approach is that TL and pleurodesis are treated in one 
procedure, but disadvantages include the requirement 
for general anaesthesia, an inpatient stay of up to 7 days 
and a postoperative serious adverse event (SAE) rate of 
17%.12
We searched MEDLINE, Embase, Cumulative Index to 
Nursing and Allied Health Literature and the Cochrane 
Library for articles about the management of TL by 
IPC and VAT-PD in patients with mesothelioma using 
the keywords ‘mesothelioma’, ‘entrap* lung*’, ‘encase* 
lung*’ or ‘restrictive pleuris*‘ or ‘unexpand* lung*'.
The prevalence of TL in MPM is poorly documented. 
In case series of malignant pleural effusion with TL, the 
underlying aetiology was MPM in 13%–37% of cases.13–15
No randomised trials comparing IPC with VAT-PD for 
management of TL in MPM (or other lung malignancy) 
have been reported. However, several small, retrospec-
tive mixed tumour type series reporting IPC use in TL 
indicate that IPCs may be safe, reasonably effective at 
controlling dyspnoea and that their use could reduce 
repeated admissions to hospital.16–18
With regard to VAT-PD, there are no published studies 
specifically addressing the management of TL in MPM. 
However, the 2011 European Respiratory Society/Euro-
pean Society of Thoracic Surgery (ERS/ESTS) MPM 
guidelines recommended that pleurectomy/decorti-
cation is considered for symptomatic patients with TL 
(recommendation grade 2C) and that a VATS approach is 
preferred (grade 1C).19 There is also little research exam-
ining the understanding of surgical treatments for MPM 
or exploring factors influencing willingness to participate 
in MPM trials or decisions regarding randomisation.
The MesoVATS trial randomised patients with MPM 
to talc pleurodesis versus VAT-partial pleurectomy.12 
Although there was no difference in median survival 
between the two arms, there was some evidence that 
surviving patients in the VAT arm had better quality 
of life from 6 months post-treatment than surviving 
patients in the talc pleurodesis arm. However, because 
of the inclusion criteria, there were very few cases of 
TL in MesoVATS, and therefore, the outcomes are not 
directly applicable to MPM with TL and pleural effusion. 
Searches on  ClinicalTrials. gov show there are no ongoing 
studies examining IPC versus VAT-PD for TL in MPM.
The rationale for undertaking the MesoTRAP study 
is to begin to provide high-quality evidence for the best 
management of TL, which affects a significant percentage 
of patients with MPM in their final months of life. TL 
is a challenging condition to manage and is associated 
with high morbidity; therefore, a study investigating the 
two most commonly used approaches, namely IPC and 
VAT-PD, is timely.
The objectives of this study are to determine whether 
it is possible to identify, recruit and randomise patients 
to a trial of insertion of an IPC versus VAT-PD in TL 
due to MPM and then, following randomisation, to 
measure dyspnoea and chest pain using visual analogue 
scale (VAS) scores, assess post-treatment complications, 
measure resource and health service use and monitor 
quality of life in each treatment group.
If the pilot clinical trial is successful in recruiting and 
randomising 38 patients in the 18-month timeline and 
there is no evidence of patient harm from study interven-
tions (when comparing one randomised group with the 
other), we plan to develop the trial into a full phase III 
study to compare the efficacy of IPC versus VAT-PD for 
managing TL with pleural effusion in MPM.
There has been one Substantial Amendment to the 
study protocol to date as described below:
Pilot clinical trial:
1. Removal of the exclusion criterion ‘IPC in situ for 
more than 28 days’.
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2. Removal of the exclusion criterion ‘Previous attempt 
at pleurodesis on ipsilateral side’.
3. Change in wording of inclusion criterion from 
‘Confirmed MPM’ to ‘Pathologically confirmed MPM’.
Overall feasibility study
1. Observational sub-study added
MEthods And AnAlysIs
study design
This is a feasibility study that includes a pilot multicentre, 
open-label randomised controlled clinical trial designed 
to measure the SD, and examine the patterns of change 
over time, of VAS scores for dyspnoea following randomi-
sation in each treatment group.
Secondary objectives of the feasibility study include 
estimation of the following:
 ► SD of VAS scores for chest pain.
 ► Quality of life at baseline, intervention, 6 weeks, 3, 6 
and 12 months postrandomisation.
 ► Survival and adverse events.
 ► The prevalence of TL in patients with MPM.
 ► The percentage of eligible patients in participating 
centres.
 ► The ability to recruit and randomise 38 patients to 
either VAT-PD versus IPC within 18 months in patients 
with TL and pleural effusion due to MPM.
 ► Completion rates for alternative forms of data capture 
for health service and resource use data for economic 
evaluation.
The full protocol is available as online supplementary 
file 1.
PIlot clInIcAl trIAl
Inclusion and exclusion criteria
The primary inclusion criterion is the presence of TL 
defined as ‘clinically significant TL requiring interven-
tion in the opinion of the clinical team’ in a patient with 
proven MPM. A pleural effusion must be present and 
the patient must be ≥18 years old, able to give informed 
consent and be considered by the clinical team to be 
expected to survive at least 4 months as well as being suit-
able for, and willing to undergo, treatment with either 
VAT-PD or IPC.
The main exclusion criteria are full lung re-expansion 
following pleural drainage and evidence of active pleural 
infection.
Patient groups
It is anticipated that eligible patients will come from one 
of two groups:
 ► Group 1: patients found to have TL following fluid 
drainage by aspiration/intercostal chest drain or 
post-thoracoscopy.
 ► Group 2: Patients found to have TL following place-
ment of IPC for management of pleural effusion. 
Patients in this group will be eligible to be recruited 
and randomised to either VAT-PD or continuation 
with the IPC as long as all other inclusion/exclusion 
criteria are met.
The study will be undertaken at mesothelioma surgical 
centres across the UK with expertise in both IPC and 
VAT-PD together with their linked non-surgical referral 
hospitals. Patients from non-surgical centres who are 
randomised to VAT-PD will be referred to their nearest 
surgical centre for the procedure to be carried out.
Participant identification and informed consent
Patients meeting the eligibility criteria will be identi-
fied and approached by the research team at their local 
centre (figure 1). Patients will be provided with a patient 
information sheet (PIS) and be given a minimum of 24 
hours to consider participation. Informed consent will be 
taken by one of the study doctors or research nurses (see 
online supplementary file 2).
A list of current participating sites is provided as online 
supplementary file 3.
randomisation
Following provision of consent, baseline measurements 
will be taken, suitable patients will be randomised and 
their procedure date will be arranged.
Patients will be randomised in a 1:1 ratio using a comput-
er-generated minimisation program with a random 
element such that each patient retains a non-zero proba-
bility of being randomised to each of the treatment arms 
and groups are well-balanced, with minimisation factors:
 ► High risk as defined by European Organisation for 
Research and Treatment of Cancer (EORTC) meso-
thelioma risk score (high/low risk).20 Patients will be 
defined as high risk if they meet three or more of:
 – White cell count >8.3×109/L, tested on the day of 
randomisation or within previous 7 days.
 – Non-epithelioid type (unknown type is classed as 
non-epithelioid).
 – Male.
 – Eastern Cooperative Oncology Group perfor-
mance status of ≥1.
 ► Previous insertion of IPC on same side as effusion 
requiring management.
Due to the nature of the interventions, there will be no 
blinding of the treatment allocations.
sample size
The sample size is chosen to be feasible within the times-
cale of the study in order to estimate the prevalence of 
TL, feasibility of recruitment and randomisation and 
estimate the SD and the patterns of change over time 
of the VAS measurements. Browne21 provides justifica-
tion of sample sizes in pilot studies and shows that a 
sample of 38 is appropriate (allowing for a 20% failure 
to record any dyspnoea), provided that any subse-
quent definitive trial is based on the 70%–80% upper 
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Figure 1 Study flow chart. IPC, indwelling pleural catheter; MPM, malignant pleural mesothelioma; VAT-PD, video-assisted 
thoracoscopic partial pleurectomy decortication. MesoTRAP Investigators (6 August 2018).
confidence limit for the SD rather than the sample esti-
mate itself. Although Teare et al 22recommends larger 
sample sizes on the basis that, over all trial phases, 
they are more efficient than inflating the SD based on 
confidence limits, a much larger study is not feasible 
within a reasonable time frame. Therefore, we take the 
approach of Browne and a sample of 38 patients.
study interventions
Unlike many clinical trials in which an investigational 
arm is compared against a standard practice arm, 
MesoTRAP is different in that there is no accepted 
standard treatment for TL in mesothelioma at present. 
MesoTRAP has been designed to begin a comparison of 
these two options in terms of patient benefit. Patients 
will only be randomised if their clinician is confident 
that they are suitable for both IPC and VAT-PD. At 
present, we do not know what the difference in patient 
benefit is between the two interventions.
Investigators at all sites agree to adhere to study-spe-
cific standard operating procedures for performing 
VAT-PD and IPC procedures.
Video-assisted thoracoscopic partial pleurectomy/decortication
Under general anaesthesia, a thoracic surgeon creates 
an initial port in the chest wall and the pleural effu-
sion is drained to dryness. Additional ports are optional 
to achieve lung expansion. Thoracotomy (with rib 
spreading) is prohibited. Sharp and blunt dissection of 
the visceral pleura is mandatory to release TL. A parietal 
pleurectomy is optional by developing an extrapleural 
plane. This dissection plane is extended as widely as 
possible. Resection of the diaphragmatic and pericar-
dial pleura are optional but not generally performed. 
At the end of the procedure, one or more intercostal 
drains are placed, with the use of suction optional. The 
median length of stay for VAT-PD was 7 days (IQR 5–11 
days) in MesoVATS.12
Indwelling pleural catheter
Inserted under local anaesthesia as a day case, a soft 
silicone IPC with a one-way valve at the distal end is 
tunnelled a few centimetres under the skin. The prox-
imal part is inserted into the pleural space, and the 
distal valve is connected to a vacuum drainage bottle. 
The IPC can be drained at home by the patient, carer 
or district nurse as often as required.
criteria for modifying or discontinuing allocated intervention
If a patient, randomised to VAT-PD deteriorates to the 
point that they are not fit enough to undergo VAT-PD, 
they will be offered an IPC instead. This decision will 
be at the discretion of the clinical team managing the 
patient and will be recorded and reported. For patients 
randomised to the IPC arm, the IPC may be removed if 
there is no significant drainage for 4 weeks and no radi-
ological evidence of significant fluid reaccumulation. 
All recruited patients will be reported.
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Table 1 Schedule of events
Specific activity Screening
Baseline/
randomisation
Intervention
(0–3 weeks 
postrandomisation)
6 
weeks±1 
week
3 
months±1
week
6 
months±1 
weeks
12 
months±1 
weeks
Check eligibility of potential 
participant
X
Provide patient information 
sheet
X
Take informed consent X
Baseline clinical data 
collection
X
Randomisation X
VAT-PD or IPC X
VAS scores for dyspnoea and 
chest pain
X X X X X X
EQ-5D and
EORTC QLQC30
X X X X X X
Review/reporting of patient 
AEs/SAEs
X X X X X X
Qualitative interviews X
Clinical follow-up data X X X X
Health service and resource 
use data
X X X X X
AEs, adverse events; EORTC, European Organisation for Research and Treatment of Cancer Quality Life Questionnaire; EQ, EuroQoL; 
IPC, indwelling pleural catheter; SAEs, serious adverse events; VAS, visual analogue scale; VAT-PD, video-assisted thoracoscopic 
partial pleurectomy/decortication.
data collection
Detailed screening logs will be collected from sites on 
a monthly basis, and these will be used to assess the 
prevalence of TL.
Patients will be followed up according to the visit 
schedule (table 1). Clinical and health resource use 
data will be collected at baseline, and the patient will 
be asked to complete two quality of life question-
naires (EQ-5D-5L and EORTC QLQC30) along with 
VAS scores for chest pain and dyspnoea. Patients 
will be given paper diaries to record their VAS score 
for chest pain and dyspnoea daily for 6 weeks, then 
weekly up to 12 months. Measurements of the VAS 
scores will be taken according to an agreed standard 
operating procedure with duplicate measurements 
being taken at the coordinating centre. Patients who 
are randomised to IPC will be given a paper diary to 
record their fluid drainage from randomisation to 
study completion.
Clinical data, adverse events, health resource use data 
and quality of life questionnaires will be completed at 
the time of the study interventions and at each follow-up 
visit. Follow-up visits at 6 weeks, 3, 6 and 12 months 
postrandomisation are planned to coincide with stan-
dard clinical care visits.
All data will be entered remotely onto a secure bespoke 
database.
Adverse events
All SAEs occurring between randomisation and the end 
of follow-up will be recorded in the hospital notes and 
case report forms. Unexpected SAEs will be submitted 
to the sponsor within 24 hours of the site becoming 
aware. The sponsor will report any unexpected SAEs 
to the Data Monitoring Committee (DMC). If an 
SAE occurs that is considered to be both unexpected 
and related to the study protocol (SUSAR), it will be 
reported within 24 hours of recognition. The sponsor 
will report any Suspected Unexpected Serious Adverse 
Reactions (SUSARs) to the research ethics committee 
within 15 days of their knowledge of the event, and 
local Principal Investigators (PIs) will be notified.
Non-SAEs will be not be recorded or reported unless 
they form part of the clinical event dataset.
statistical analysis
Primary analysis
The SD for the VAS dyspnoea score to be used in a 
phase III trial will be estimated as the 70% upper limit 
of the CI as recommended in Browne.21 The patterns 
of change over time will be assessed using descriptive 
statistics and graphical representations.
Our primary analysis will use the intention to treat, 
since this will give a more reproducible estimate of the 
treatment effect and its SD, although we will investigate 
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Table 2 MesoTRAP investigators (6 August 2018)
Mr Kelvin Lau St Bartholomew's Hospital, London
Mr M Nidal Bittar Victoria Hospital, Blackpool
Mr Antonio Martin-
Ucar
University Hospitals, Coventry
Dr Jurgen Herre Cambridge University Hospitals
Dr Paul Beckett Royal Derby Hospital
Mr Alan Kirk Golden Jubilee National Hospital, 
Scotland
Dr Kevin Blyth Queen Elizabeth University Hospital, 
Glasgow
Mr Apostolos 
Nakas
Glenfield Hospital, Leicester
Dr Eleanor Mishra Norfolk and Norwich University 
Hospitals
Dr Shahul Khan Royal Stoke University Hospital
Dr Helen Roberts Nottingham University Hospitals NHS 
Trust
Mr Dionisios 
Stavroulis
John Radcliffe Hospital, Oxford
Dr Louise Brown The Pennine Acute Hospitals NHS 
Trust
Dr Mohammed 
Munawar
LancashireTeaching Hospitals
Dr Matthew Evison University Hospital of South 
Manchester
any disagreement between this and the per protocol 
estimate.
Secondary analyses
i. The SD for the VAS chest pain score to be used in 
a phase III trial will be estimated as the 70% upper 
limit of the CI as recommended in Browne.21 The 
patterns of change over time will be assessed using 
descriptive statistics and graphical representations.
ii. EQ-5D-5L and EORTC QLQ-C30 scores will be sum-
marised by treatment group via descriptive statistics 
in order to examine quality of life post-intervention. 
Scores will also be summarised descriptively and 
graphically over time in order to assess patterns of 
change. Questionnaire completion rates and data 
quality will be examined.
iii. The survival rate at 30 days and 12 months postran-
domisation will be summarised by treatment arm.
iv. SAEs will be recorded from randomisation until the 
end of the follow-up period and will be reported by 
treatment group.
v. The recruitment rate will be estimated as the num-
ber of patients with TL due to MPM recruited, divid-
ed by the number of respective patients identified as 
eligible; it will be expressed as a rate per centre, per 
month open for recruitment.
vi. The prevalence of TL in patients with MPM will be 
estimated as the number of MPM patients with pleu-
ral effusion and TL divided by the number of MPM 
patients within the 18-month study period. This will 
be multiplied by 100 and reported as a percentage.
vii. The percentage of eligible patients in participating 
centres will be estimated as the number of eligible 
patients divided by the number of MPM patients with 
TL screened in each centre, multiplied by 100.
A detailed statistical analysis plan will be finalised 
before the end of recruitment. Briefly, the repeated 
assessments of continuous measurements (postrandomi-
sation VAS scores for dyspnoea and pain and quality of 
life indices) will be analysed using linear mixed models, 
exploring linear and higher polynomial relationships 
between outcomes and time after randomisation. Patients 
will be included as random effects on the intercept and, 
if appropriate, the coefficients. The baseline measure-
ments, treatment arm, (if possible) minimisation factors 
and time since randomisation will be included as fixed 
effects. A treatment by time interaction will also be inves-
tigated. Models will be fitted using restricted maximum 
likelihood, and all point estimates and components of 
variation will be retrieved. Model assessment will be by 
examination of residuals and influence statistics.
Mean differences between outcomes, overall and 
restricted to the first year after randomisation will be 
taken as the primary measures of treatment effect. 
Patients who die will be assigned the worst score possible 
(100 for dyspnoea and pain) and the area under the VAS 
curve for each patient, estimated from the above models, 
will be calculated. The variance of these outcomes will be 
estimated from the models and used in the sample size 
estimates for a phase III trial.
No subgroup analyses are planned.
trial oversight
The Trial Management Group, responsible for the 
day-to-day running of the overall feasibility study, will 
meet at least every 2 months to discuss recruitment, 
safety, data management and local site issues.
The Trial Steering Committee will meet 6 monthly (or 
more frequently if necessary) to monitor and supervise 
the trial, to ensure it is being conducted according to the 
protocol and timelines, to review any relevant informa-
tion from other sources (eg, other related trials) and to 
consider recommendations from the DMC.
Annual DMC meetings will review progress against 
the agreed milestones, recruitment and safety. The 
committee will consist of experienced, independent 
personnel. The DMC will meet after the first 15 patients 
are randomised to review the data for safety. Meetings 
will be held as necessary should urgent issues arise.
Data monitoring will be conducted remotely by the trial 
manager and data manager. Site visits will be conducted 
if triggered, for example, by safety concerns or suspected 
protocol non-compliance.
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hEAlth EconoMIc fEAsIbIlIty study
During the trial, the economic study will evaluate alterna-
tive data collection mechanisms, with a view to informing 
future trial design. It will therefore:
1. Design bespoke data collection forms for interven-
tions and their follow-up, with inputs from individual 
study centres.
2. Evaluate the suitability of collecting follow-up health 
services use data from patients and via routine data 
sources.
3. Develop a data collection and analysis plan for a future 
trial.
obsErvAtIonAl substudy
In parallel with the main study, an observational substudy 
will collect observational data on a cohort of patients 
who have MPM and TL but who are either not eligible 
to participate, or who decline to participate in the main 
study. Patients in the observational substudy will receive 
the same baseline and follow-up visits as those in the main 
study but will receive standard clinical care.
The main inclusion criterial are pathologically 
confirmed MPM and the presence of TL, defined as a 
‘clinically significant TL in the opinion of the clinical 
team’. Patients must also be ≥18 years old and able to give 
informed consent. The only exclusion criterion is the 
lung re-expanding fully following pleural fluid drainage, 
that is, no entrapment.
Patients meeting the eligibility criteria will be informed 
about the study, provided with a PIS and given at least 
1 hour to consider participation. A member of the 
research team will address any questions and take written 
informed consent (see online supplementary file 4).
Following provision of consent the baseline visit will be 
conducted, with follow-up visits at 6 weeks, 3, 6 and 12 
months postbaseline. Patient follow-up and data collec-
tion will match that used in the pilot clinical trial.
QuAlItAtIvE substudy
A qualitative substudy will also examine patient experi-
ence of the interventions and factors influencing patient 
decisions to participate and accept randomisation or 
not. Five patients randomised to the VAT-PD group, 
five patients randomised to the IPC group and five who 
decline participation will be recruited to participate in 
a semistructured interview. Informed consent will take 
place at the patient’s local participating centre (see 
online supplementary file 5), and patient will undergo 
a telephone interview with a specialist nurse from the 
coordinating centre. Framework analysis methods will 
be used.23 The interviews will explore the following ques-
tions:
1. What is the patient experience of the MesoTRAP re-
cruitment process?
2. What factors influence patient decisions regarding Me-
soTRAP including participation and randomisation?
3. What is the patient experience of MesoTRAP study in-
terventions?
4. What are the implications of the findings for 
MesoTRAP if it moves to a full study in terms of design, 
patient information and support?
EthIcs And dIssEMInAtIon
We aim to publish the outputs of this work in an inter-
national peer reviewed journal compliant with an Open 
Access policy. The work will be submitted to major national 
and international clinical meetings and we will inform 
patient with mesothelioma/carer support groups of the 
results including Mesothelioma UK, Clydeside Action on 
Asbestos, Mick Knighton Mesothelioma Research Fund 
and the Greater Manchester Asbestos Victims Support 
Group, a number of whom produce newsletters for their 
members/supporters.
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